Propanc Biopharma Expands Anti-Aging Research with Spanish Universities

Event summary

  • Propanc Biopharma has entered a multi-year research collaboration with the Universities of Jaén and Granada, Spain, marking the fifth such agreement over 17 years.
  • The collaboration will focus on senescence modulation and fibrosis/cancer-related patent support, utilizing compounds and research groups from both universities.
  • Professors Macarena Perán Quesada (UJA) and Juan Antonio Marchal Corrales (UGR) will lead the research efforts, supported by postdoctoral fellows.
  • The collaboration aims to strengthen Propanc’s intellectual property and explore the potential of PRP technology in treating age-related diseases and resistant tumors.
  • Propanc is preparing its lead asset, PRP, for a Phase 1b First-In-Human study in advanced cancer patients later in 2026.

The big picture

Propanc's continued reliance on university partnerships for research highlights the challenges of early-stage biopharmaceutical development and the need for external expertise. The focus on senescence modulation aligns with the growing interest in anti-aging therapies, a market with potentially significant, but also highly speculative, long-term value. The company's strategy of expanding PRP's therapeutic potential beyond cancer into age-related diseases represents a significant pivot, increasing both the potential reward and the inherent risk profile.

What we're watching

Clinical Progress
The success of the upcoming Phase 1b trial for PRP will be a key indicator of the technology's viability and potential for broader application, given the company's stated ambitions.
IP Protection
The extent to which the collaboration yields defensible patents will determine the long-term value of Propanc's intellectual property portfolio and its competitive advantage.
Funding Needs
Given the multi-year nature of the collaboration and the ongoing clinical development of PRP, Propanc will likely require additional funding to sustain its research and development efforts.

Related topics

Patent Filing